BOLAR's GENERIC DYAZIDE ANDA WILL BE WITHDRAWN BY FDA, AGENCY NOTIFIES FIRM AUG. 28; BIOEQUIVALENCE RATING IS DOWNGRADED TO "BX" IN THE MEANTIME

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".